PlaqueTec, the Cambridge-based company pioneering the development a biomarker-based approach to transform the understanding of coronary artery disease (CAD), the leading cause of death worldwide, has announced the appointment of Dr Tim Brears as chief executive.
Dr Brears has many years’ experience in the biopharmaceutical industry and was, until recently, Chief Executive of Xention Limited, a company he founded in 2002 and which has become a leader in the development of drugs for the control of atrial fibrillation.
Prior to forming Xention, he was Chief Executive of Gendaq Limited, a gene-regulation company, which was acquired by Sangamo Biosciences in 2001. From 1993 to 1999 he was director of licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina. Tim graduated from Oxford University in 1983 and was awarded a PhD from Cambridge University in 1987. He subsequently held an EMBO post-doctoral fellowship at Rockefeller University, New York. He holds an MBA from Duke University’s Fuqua School of Business and is a registered US patent agent.
PlaqueTec is capitalizing on the lack of biomarkers available to inform the development of new cardiovascular drugs. Its proprietary technology can be used to assess the performance and potential differentiation of existing drugs, to facilitate the development of new drugs, to better understand mechanisms for the treatment of CAD, to develop patient-specific information and more accurately predict the risk of heart attack and to stratify target populations for specific drug therapies. The company’s approach has been validated in two clinical studies to date.
Commenting on his appointment, Jon Moynihan, chairman of PlaqueTec and principal of Ipex Capital, PlaqueTec’s major investor, said: ‘We are delighted to have Tim on board. He brings significant experience in management and commercial development, and his background in the cardiovascular sector will be especially valuable to PlaqueTec’.
Tim Brears commented: ‘PlaqueTec has a pioneering technology and is entering an exciting stage of its development as it starts to enter partnerships for its novel approach in coronary artery disease. I look forward to working with the PlaqueTec team, which has made tremendous progress in establishing the company as a leader in this area.’